Kura Oncology Nets $135M KOMZIFTI Milestone, Q4 Loss Narrows to $8M
Kura Oncology booked $2.1 million of KOMZIFTI net product revenue and triggered $135 million in milestone payments in Q4 2025, while collaboration revenue fell to $15.2 million from $53.9 million year-over-year. R&D investment rose to $64.4 million and net loss narrowed to $8 million on cash reserves of $667.2 million.
1. KOMZIFTI Commercial Launch
Kura Oncology achieved FDA approval for KOMZIFTI and recorded $2.1 million in net product revenue during Q4 2025, triggering a $135 million milestone payment tied to its first commercial sale. The new menin inhibitor also secured patent protection through July 2044 and category 2A NCCN guidelines listing.
2. Financial Results Overview
Total collaboration revenue declined to $15.2 million from $53.9 million in Q4 2024 due to decreased partner milestones, while R&D expenses climbed to $64.4 million and SG&A expenses rose to $39.1 million, reflecting expanded development and commercial activities.
3. Improved Loss and Cash Position
Net loss improved to $8 million from $19.2 million a year earlier, benefiting from KOMZIFTI revenues and milestone income. Cash and short-term investments stood at $667.2 million as of December 31, 2025, down from $727.4 million, supporting ongoing trials and launch efforts.
4. Pipeline and Market Expansion
The company anticipates multiple clinical updates across solid tumors and combination therapies in 2026 while working to expand payer coverage beyond the current 84%. Executives emphasize the importance of demonstrating combination efficacy to capture market share against competing menin inhibitors.